Search results
Prostate cancer: Supplement, keto diet may boost immunotherapy
Medical News Today· 5 days agoAbout 13% of cisgender men around the world will receive a prostate cancer diagnosis in their...
...Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across...
Digital Journal· 23 hours ago“The TACT 5-year clinical trial data, along with multiple real-world reports on the safety, efficacy and durability of TULSA from U...
O.J. Simpson died from prostate cancer, not COVID-19 vaccine | Fact check
USA TODAY via Yahoo News· 4 days agoA television news outlet in Florida reported in February, about two months before Simpson's death, that he had been diagnosed with prostate cancer. A statement released by ...
Earnings call: FibroGen reports Q1 2024 results, optimistic about pipeline By Investing.com
Investing.com· 10 hours agoThe company highlighted the upcoming top line data from Phase 3 studies for pamrevlumab in...
Guy Carbonneau helps shed light on men’s health | Montréal Canadiens
NHL· 5 days agoRecently, the three-time Stanley Cup champion teamed up with Pros Talk Prostate, a men’s health...
Citi cuts ORIC Pharmaceuticals stock price target post 1Q24 pipeline update By Investing.com
Investing.com· 8 hours agoORIC Pharmaceuticals is set to begin combination trials for its drug candidate, ORIC-944, a PRC2...
Jay Bothroyd hoping new project shows that ‘golf can be fun and is for everyone’
PA Media: Sport via Yahoo Sports· 6 days agoBothroyd – who is supporting Prostate Cancer UK’s Big Golf Race fundraising challenge this summer –...
FibroGen Shares Climb On Strong Q1 Sales - FibroGen (NASDAQ:FGEN)
Benzinga· 2 hours agoFibroGen, Inc. FGEN shares are trading higher Tuesday after the company posted mixed first-quarter...
Johnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest Data
Benzinga via Yahoo Finance· 23 hours agoOn Sunday, Johnson & Johnson (NYSE:JNJ) ) released updated results from an open-label, multicenter,...
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical...
St. Louis Post-Dispatch· 4 days agoJohnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT ...